BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kohonen-corish MR, Cooper WA, Saab J, Thompson JF, Trent RJ, Millward MJ. Promoter Hypermethylation of the O6-Methylguanine DNA Methyltransferase Gene and Microsatellite Instability in Metastatic Melanoma. Journal of Investigative Dermatology 2006;126:167-71. [DOI: 10.1038/sj.jid.5700005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010;8:56. [PMID: 20540720 DOI: 10.1186/1479-5876-8-56] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
2 Cesinaro A, Sartori G, Migaldi M, Schirosi L, Pellacani G, Collina G, Maiorana A. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology 2012;44:313-7. [DOI: 10.1097/pat.0b013e328353a0ff] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
3 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Reference Citation Analysis]
4 Tronov VA, Artamonov DN, Gorbacheva LB. Genetic markers of melanoma. Russ J Genet 2010;46:146-56. [DOI: 10.1134/s1022795410020031] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Cooper WA, Kohonen-Corish MR, Chan C, Kwun SY, McCaughan B, Kennedy C, Sutherland RL, Lee CS. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 2008;52:613-22. [PMID: 18370958 DOI: 10.1111/j.1365-2559.2008.02999.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
6 van den Hurk K, Niessen HE, Veeck J, van den Oord JJ, van Steensel MA, Zur Hausen A, van Engeland M, Winnepenninckx VJ. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta 2012;1826:89-102. [PMID: 22503822 DOI: 10.1016/j.bbcan.2012.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 35] [Article Influence: 1.0] [Reference Citation Analysis]
7 Christmann M, Kaina B. Epigenetic regulation of DNA repair genes and implications for tumor therapy. Mutat Res Rev Mutat Res 2019;780:15-28. [PMID: 31395346 DOI: 10.1016/j.mrrev.2017.10.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
8 Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010;20:253-65. [PMID: 20418788 DOI: 10.1097/CMR.0b013e328338a35a] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
9 Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirniö P, Karttunen TJ, Mäkinen MJ. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology. 2011;58:679-692. [PMID: 21457162 DOI: 10.1111/j.1365-2559.2011.03821.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
10 Deng T, Kuang Y, Wang L, Li J, Wang Z, Fei J. An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. Biochem Biophys Res Commun 2009;387:611-6. [PMID: 19632198 DOI: 10.1016/j.bbrc.2009.07.093] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
11 Voelter V, Diserens AC, Moulin A, Nagel G, Yan P, Migliavacca E, Rimoldi D, Hamou MF, Kaina B, Leyvraz S, Hegi ME. Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int J Cancer 2008;123:1215-8. [PMID: 18546261 DOI: 10.1002/ijc.23632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
12 Goodwin CR, Liang L, Abu-Bonsrah N, Hdeib A, Elder BD, Kosztowski T, Bettegowda C, Laterra J, Burger P, Sciubba DM. Extraneural Glioblastoma Multiforme Vertebral Metastasis. World Neurosurg 2016;89:578-582.e3. [PMID: 26704201 DOI: 10.1016/j.wneu.2015.11.061] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
13 Johansen MD, Rochat P, Law I, Scheie D, Poulsen HS, Muhic A. Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature. Case Rep Oncol Med 2016;2016:8190950. [PMID: 27247816 DOI: 10.1155/2016/8190950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mitsiogianni M, Amery T, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. From chemo-prevention to epigenetic regulation: The role of isothiocyanates in skin cancer prevention. Pharmacology & Therapeutics 2018;190:187-201. [DOI: 10.1016/j.pharmthera.2018.06.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
15 Chen TC, Chan N, Minea RO, Hartman H, Hofman FM, Schönthal AH. Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. Cancers (Basel) 2018;10:E362. [PMID: 30274152 DOI: 10.3390/cancers10100362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007;115:1161-76. [PMID: 18042149 DOI: 10.1111/j.1600-0463.2007.apm_855.xml.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 7.7] [Reference Citation Analysis]
17 Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer. 2010;103:820-826. [PMID: 20736948 DOI: 10.1038/sj.bjc.6605796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
18 Guo Y, Long J, Lei S. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis. J Cell Physiol 2019;234:7356-67. [PMID: 30370527 DOI: 10.1002/jcp.27495] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
19 Qi F, Yin Z, Wang G, Zeng S. Clinical and Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Melanoma: A Systematic Meta-Analysis. Ann Dermatol 2018;30:129-35. [PMID: 29606808 DOI: 10.5021/ad.2018.30.2.129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011;1816:179-90. [PMID: 21745538 DOI: 10.1016/j.bbcan.2011.06.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 84] [Article Influence: 4.2] [Reference Citation Analysis]
21 Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99:375-82. [PMID: 18594535 DOI: 10.1038/sj.bjc.6604452] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
22 Moran B, Silva R, Perry AS, Gallagher WM. Epigenetics of malignant melanoma. Semin Cancer Biol 2018;51:80-8. [PMID: 29074395 DOI: 10.1016/j.semcancer.2017.10.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
23 Khattab MH, Marciscano AE, Lo SS, Lim M, Laterra JJ, Kleinberg LR, Redmond KJ. Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Rep Oncol Med 2015;2015:431819. [PMID: 26199775 DOI: 10.1155/2015/431819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
24 Kubecek O, Trojanova P, Molnarova V, Kopecky J. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Medical Hypotheses 2016;93:74-6. [DOI: 10.1016/j.mehy.2016.05.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Luan XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou J. Extracranial multiorgan metastasis from primary glioblastoma: A case report. World J Clin Cases 2021; 9(33): 10300-10307 [PMID: 34904103 DOI: 10.12998/wjcc.v9.i33.10300] [Reference Citation Analysis]